Lisata Therapeutics, Inc. (LSTA)
(Delayed Data from NSDQ)
$2.94 USD
+0.01 (0.36%)
Updated Aug 6, 2024 03:39 PM ET
After-Market: $3.00 +0.06 (2.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
LSTA 2.94 +0.01(0.36%)
Will LSTA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LSTA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LSTA
Quest Diagnostics' (DGX) Haystack Oncology Forges New MRD Deal
Lisata (LSTA) Stock Rallies More Than 30% YTD: Here's Why
LSTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lisata's (LSTA) LSTA1 Gets FDA Orphan Drug Tag for Osteosarcoma
Lisata's (LSTA) LSTA1 Gets FDA's RPDD Tag for Osteosarcoma
Lisata (LSTA) Stock Up More Than 35% in 3 Months: Here's Why
Other News for LSTA
Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024
Lisata Therapeutics treatment of cholangiocarcinoma granted FDA orphan status
Lisata Therapeutics: A Strong Buy on Revolutionary Cancer Treatment Advancements
Lisata to use Haystack technology to evaluate pancreatic cancer asset certepetide
Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD? Technology to Evaluate Efficacy of Pancreatic Cancer Therapy